[293] Sun YF, Xu Y, Yang XR, et al. Circulating stem
cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor
prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology,
2013, 57(4): 1458-68. [294] Guo W, Yang XR, Sun YF, et al. Clinical
significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular
carcinoma by an optimized negative enrichment and qRT-PCR-based platform[J].
Clin Cancer Res, 2014, 20(18):4794-805. [295] Sun YF, Guo W, Xu Y, et al. Circulating Tumor
Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial
and Mesenchymal Composition and Distinct Clinical Significance in
Hepatocellular Carcinoma[J]. Clin Cancer Res, 2018, 24(3): 547-59. [296] Qu C, Wang Y, Wang P, et al. Detection of
early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive
individuals by liquid biopsy[J]. Proc Natl Acad Sci U S A, 2019, 116(13):
6308-12. [297] Huang A, Zhang X, Zhou SL, et al. Plasma
Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and
Surveillance in Patients with Hepatocellular Carcinoma[J]. J Cancer, 2016,
7(13): 1798-803. [298] Huang A, Zhao X, Yang XR, et al. Circumventing
intratumoral heterogeneity to identify potential therapeutic targets in
hepatocellular carcinoma[J]. J Hepatol, 2017, 67(2): 293-301. [299] Huang A, Zhang X, Zhou SL, et al. Detecting
Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet
Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity[J]. J Cancer,
2016, 7(13): 1907-14. [300] Cai J, Chen L, Zhang Z, et al. Genome-wide
mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a
non-invasive approach for early detection of hepatocellular carcinoma[J]. Gut,
2019, 68(12): 2195-205. [301] Li W, Zhang X, Lu X, et al.
5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic
biomarkers for human cancers[J]. Cell Res, 2017, 27(10):1243-57. [302] Llovet JM, Montal R, Sia D, et al. Molecular
therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin
Oncol, 2018, 15(10): 599-616. [303] Gao Q, Zhu H, Dong L, et al. Integrated
Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma[J].
Cell, 2019, 179(2): 561-77.e22. [304] Jiang Y, Sun A, Zhao Y, et al. Proteomics
identifies new therapeutic targets of early-stage hepatocellular carcinoma[J].
Nature, 2019, 567(7747): 257-61. [305] Shi J, Lai EC, Li N, et al. Surgical treatment
of hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol,
2010, 17(8): 2073-80. [306] Japan LCSGO. General rules for the clinical and
pathological study of primary liver cancer[M]. Tokyo: Kanehara: 2003. [307] Kondo M, Morimoto M, Kobayashi S, et al. Randomized,
phase II trial of sequential hepatic arterial infusion chemotherapy and
sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular
carcinoma: SCOOP-2 trial[J]. BMC Cancer, 2019, 19(1): 954. [308] Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib
plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy
versus sorafenib alone in patients with advanced hepatocellular carcinoma
(SILIUS): a randomised, open label, phase 3 trial[J]. Lancet Gastroenterol
Hepatol, 2018, 3(6): 424-32. [309] Lyu N, Lin Y, Kong Y, et al. FOXAI: a phase II
trial evaluating the efficacy and safety of hepatic arterial infusion of
oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular
carcinoma[J]. Gut, 2018, 67(2): 395-6. [310] Wang Q, Xia D, Bai W, et al. Development of a
prognostic score for recommended TACE candidates with hepatocellular carcinoma:
A multicentre observational study[J]. J Hepatol, 2019, 70(5): 893-903. [311] Xu L, Peng ZW, Chen MS, et al. Prognostic nomogram
for patients with unresectable hepatocellular carcinoma after transcatheter
arterial chemoembolization[J]. J Hepatol, 2015, 63(1): 122-30. [312] Han G, Berhane S, Toyoda H, et al. Prediction of
Survival Among Patients Receiving Transarterial Chemoembolization for
Hepatocellular Carcinoma: A Response-Based Approach[J]. Hepatology, 2020,
72(1): 198-212. [313] Kudo M, Ueshima K, Ikeda M, et al. Randomised,
multicentre prospective trial of transarterial chemoembolisation (TACE) plus
sorafenib as compared with TACE alone in patients with hepatocellular
carcinoma: TACTICS trial[J]. Gut, 2020,69(8):1492-501. [314] Chang X, Lu X, Guo J, et al. Interventional
therapy combined with immune checkpoint inhibitors: Emerging opportunities for
cancer treatment in the era of immunotherapy[J]. Cancer Treat Rev, 2019, 74:
49-60. [315] Marks LB, Yorke ED, Jackson A, et al. Use of
normal tissue complication probability models in the clinic[J]. Int J Radiat
Oncol Biol Phys, 2010, 76(3 Suppl):S10-9. [316] Pan CC, Kavanagh BD, Dawson LA, et al.
Radiation-associated liver injury[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3
Suppl): S94-100. [317] Chon YE, Seong J, Kim BK, et al. Gastroduodenal
complications after concurrent chemoradiation therapy in patients with
hepatocellular carcinoma:endoscopic findings and risk factors[J]. Int J Radiat
Oncol Biol Phys, 2011, 81(5):1343-51. [318] Hanna GG, Murray L, Patel R, et al. UK Consensus
on Normal Tissue Dose Constraints for Stereotactic Radiotherapy[J]. Clin Oncol
(R Coll Radiol), 2018, 30(1):5-14. [319] El-Khoueiry AB, Sangro B, Yau T, et al.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):
an open-label, non-comparative, phase 1/2 dose escalation and expansion
trial[J]. Lancet, 2017, 389(10088): 2492-502. [320] Sangro B, Park J-W, Finn RS. CheckMate 459:
long-term survival outcomes with nivolumab versus sorafenib as first-line
treatment in patients with advanced hepatocellular carcinoma[C]. ESMO-GI, 2020.
[321] Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab
As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in
KEYNOTE-240: A Randomized, Double-Blind, Phase III rial[J]. J Clin Oncol, 2020,
38(3): 193-202. [322]https://www.merck.com/news/merck-announces-keytruda-pembrolizumab-met-p rimary-endpoint-of-overall-survival-os-in-patients-with-advanced-hepatocellular-carci
noma-previousily-treated-with-sorafenib. [323] Zhang Y XJ, Shen J. Update on overall survival
(OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination
with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC ）
[J]. J Clin Oncol, 2021, 39(15_suppl): abstr 4076. [324] Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study
of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular
Carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-70. [325] Llovet J, Finn RS, Ikeda M, et al. A phase 1b
trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable
hepatocellular carcinoma (uHCC):updated results[J]. Annals of Oncology, 2019,
30(suppl_5): v253-v324. [326] Qin S, Chen Z, Liu Y, et al. A phase II study of
anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line
therapy for advanced hepatocellular carcinoma or biliary tract cancer[J]. J
Clin Oncol, 2019, 37(15_suppl): abstr 4074. [327] El-Khoueiry AB, Yau T, Kang Y-K, et al.
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with
advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate
040[J]. J Clin Oncol, 2021, 39(3_suppl):abstr 269. [328] Kelley RK, Sangro B, Harris WP, et al. Efficacy,
tolerability, and biologic activity of a novel regimen of tremelimumab (T) in
combination with durvalumab (D) for patients (pts) with advanced hepatocellular
carcinoma (aHCC)[J]. J Clin Oncol, 2020, 38(15_suppl): abstr 4508.
[329] Han C, Ye S, Hu C, et al. Clinical Activity and
Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for
Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II
Trial (AK105-203)[J]. Front Oncol, 2021, 11: 684867. |
